Hanall Biopharma Past Earnings Performance
Past criteria checks 3/6
Hanall Biopharma's earnings have been declining at an average annual rate of -23.1%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 5.6% per year. Hanall Biopharma's return on equity is 1.9%, and it has net margins of 2.6%.
Key information
-23.1%
Earnings growth rate
-23.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 5.6% |
| Return on equity | 1.9% |
| Net Margin | 2.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings
Mar 13
Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?
Dec 14
Recent updates
There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings
Mar 13Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years
Feb 12What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?
Jan 25Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Jan 04Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?
Dec 14Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching
Nov 21Revenue & Expenses BreakdownBeta
How Hanall Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 134,910 | 3,509 | 48,039 | 23,945 |
| 30 Sep 23 | 133,308 | 6,049 | 46,106 | 23,701 |
| 30 Jun 23 | 129,981 | 6,464 | 44,765 | 23,374 |
| 31 Mar 23 | 114,812 | -919 | 43,862 | 19,276 |
| 31 Dec 22 | 109,995 | 251 | 42,647 | 16,498 |
| 30 Sep 22 | 104,764 | -376 | 41,420 | 13,877 |
| 30 Jun 22 | 100,596 | 949 | 39,801 | 12,236 |
| 31 Mar 22 | 97,783 | 4,288 | 38,883 | 11,089 |
| 31 Dec 21 | 101,594 | 8,896 | 38,450 | 10,462 |
| 30 Sep 21 | 98,500 | 16,123 | 37,455 | 10,238 |
| 30 Jun 21 | 95,140 | 17,778 | 36,391 | 9,783 |
| 31 Mar 21 | 94,304 | 20,413 | 35,412 | 9,789 |
| 31 Dec 20 | 88,602 | 19,765 | 34,137 | 9,316 |
| 30 Sep 20 | 92,953 | 19,714 | 33,781 | 8,018 |
| 30 Jun 20 | 98,834 | 21,457 | 33,991 | 8,769 |
| 31 Mar 20 | 106,049 | 19,753 | 34,243 | 9,279 |
| 31 Dec 19 | 108,452 | 19,174 | 34,274 | 10,051 |
| 30 Sep 19 | 105,550 | 10,279 | 34,952 | 10,263 |
| 30 Jun 19 | 101,531 | 7,373 | 34,100 | 9,295 |
| 31 Mar 19 | 94,252 | 5,882 | 32,539 | 9,401 |
| 31 Dec 18 | 91,839 | 3,300 | 31,719 | 10,545 |
| 30 Sep 18 | 88,551 | 9,000 | 29,267 | 10,123 |
| 30 Jun 18 | 89,131 | 9,149 | 27,993 | 12,308 |
| 31 Mar 18 | 87,204 | 6,945 | 27,822 | 11,837 |
| 31 Dec 17 | 84,231 | 5,813 | 27,933 | 9,790 |
| 30 Sep 17 | 85,417 | 3,586 | 27,115 | 11,789 |
| 30 Jun 17 | 81,809 | 562 | 27,597 | 10,210 |
| 31 Mar 17 | 81,807 | 1,355 | 27,941 | 9,386 |
| 31 Dec 16 | 82,882 | 2,026 | 27,660 | 9,003 |
| 30 Sep 16 | 82,223 | -3,478 | 30,827 | 7,526 |
| 30 Jun 16 | 79,584 | -5,817 | 32,400 | 6,332 |
| 31 Mar 16 | 79,447 | -7,142 | 32,814 | 5,921 |
| 31 Dec 15 | 80,023 | -7,077 | 33,227 | 6,066 |
| 30 Sep 15 | 79,818 | -16,050 | 32,121 | 6,572 |
| 30 Jun 15 | 81,892 | -13,143 | 31,251 | 6,586 |
| 31 Mar 15 | 81,657 | -12,865 | 30,558 | 7,489 |
| 31 Dec 14 | 80,880 | -12,658 | 29,786 | 7,795 |
| 30 Sep 14 | 78,763 | -11,694 | 31,527 | 8,025 |
| 30 Jun 14 | 77,511 | -17,134 | 32,529 | 9,273 |
| 31 Mar 14 | 76,276 | -18,966 | 33,413 | 9,354 |
| 31 Dec 13 | 74,228 | -21,499 | 33,682 | 9,507 |
| 30 Sep 13 | 74,338 | -9,978 | 31,171 | 9,828 |
| 30 Jun 13 | 76,161 | -4,201 | 29,694 | 8,526 |
Quality Earnings: A009420 has a large one-off gain of ₩1.1B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: A009420's current net profit margins (2.6%) are higher than last year (0.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A009420's earnings have declined by 23.1% per year over the past 5 years.
Accelerating Growth: A009420's earnings growth over the past year (1295.2%) exceeds its 5-year average (-23.1% per year).
Earnings vs Industry: A009420 earnings growth over the past year (1295.2%) exceeded the Pharmaceuticals industry 36.1%.
Return on Equity
High ROE: A009420's Return on Equity (1.9%) is considered low.